Archive for the ‘genetics’ category: Page 131
Jul 3, 2022
Brainwashing & Mind Control
Posted by Dan Breeden in categories: cybercrime/malcode, genetics, neuroscience
The CCP
Use my link http://www.audible.com/isaac or text “ISAAC” to 500–500 to get a free book including a copy of George Orwell’s “1984” and a 30-day free trial of Audible.
We often worry about the possibility of a civilization developing methods of brainwashing to indoctrinate its population and turning into a totalitarian dictatorship. We will examine both existing and possible future methods and technologies for mind control, such as neuro-hacking and genetic programming, as well as the possible defenses against such brainwashing or conditioning and implications it has for civilization.
Jul 3, 2022
Lithocholic Acid: A Gut Bacterial Metabolite That Extends Lifespan
Posted by Mike Lustgarten in categories: genetics, life extension, neuroscience
Jul 2, 2022
Study of Penn Patients with Decade-Long Leukemia Remissions after CAR T Cell Therapy Reveals New Details About Persistence of Personalized “Living Drug” Cells
Posted by Omuterema Akhahenda in categories: biotech/medical, genetics
PHILADELPHIA — In the summer of 2010, Bill Ludwig and Doug Olson were battling an insidious blood cancer called chronic lymphocytic leukemia (CLL). They’d both received numerous treatments, and as remaining options became scarce, they volunteered to become the first participants in a clinical trial of an experimental therapy underway at the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania. The treatment would eradicate their end-stage leukemia, generate headlines across the globe, and usher in a new era of highly personalized medicine. Called Chimeric Antigen Receptor (CAR) T cells, these genetically modified tumor-targeting cells are a living drug made for each patient out of their own cells. Today, an analysis of these two patients published in Nature from the Penn researchers and colleagues from Children’s Hospital of Philadelphia explains the longest persistence of CAR T cell therapy recorded to date against CLL, and shows that the CAR T cells remained detectable at least a decade after infusion, with sustained remission in both patients.
PHILADELPHIA — In the summer of 2010, Bill Ludwig and Doug Olson were battling an insidious blood cancer called chronic lymphocytic leukemia (CLL). They’d both received numerous treatments, and as remaining options became scarce, they volunteered to become the first participants in a clinical trial of an experimental therapy underway at the “This long-term remission is remarkable, and witnessing patients living cancer-free is a testament to the tremendous potency of this “living drug” that works effectively against cancer cells,” said first author J. Joseph Melenhorst, PhD, a research professor of Pathology and Laboratory Medicine at Penn. “Witnessing our patients respond well to this innovative cellular therapy makes all of our efforts so worthwhile. being able to give them more time to live and to spend it with loved ones.”
CLL, the first cancer in which CAR T cells were studied and used at Penn, is the most common type of leukemia in adults. While treatment of the disease has improved, it remains incurable with standard approaches. Eventually, patients can become resistant to most therapies, and many still die of their disease.
Jul 2, 2022
Dr Katcher’s E5 Experiment June 2022 Update | Review
Posted by Montie Adkins in categories: biotech/medical, genetics, life extension
Earlier I posted results. Those posts did not include info here concerning topical E5 human trials to start in a month or so and if the results are good they will start up a U.S. factory. So far, 3 treated rats have a 13% longer lifespan than the max for a lab rat and 3 of them are still alive.
In this video we report on the June 2022 update from Dr. Katcher’s experiment with E5, where he is testing to see how long the rats will stay alive if they are given an E5 injection every 90 days. The experiment appears to be coming to an end with only 3 treated rats still alive. But a new experiment has started as well as a human trial of E5 used topically being planned.
Continue reading “Dr Katcher’s E5 Experiment June 2022 Update | Review” »
Jul 2, 2022
UCI-led team discovers signaling molecule that potently stimulates hair growth
Posted by Kelvin Dafiaghor in categories: biotech/medical, genetics
Irvine, Calif., June 30, 2022 — University of California, Irvine-led researchers have discovered that a signaling molecule called SCUBE3 potently stimulates hair growth and may offer a therapeutic treatment for androgenetic alopecia, a common form of hair loss in both women and men.
The study, published online today in Developmental Cell, determined the precise mechanism by which the dermal papilla cells – specialized signal-making fibroblasts at the bottom of each hair follicle – promote new growth. Although it’s well known that dermal papilla cells play a pivotal role in controlling hair growth, the genetic basis of the activating molecules involved has been poorly understood.
“At different times during the hair follicle life cycle, the very same dermal papilla cells can send signals that either keep follicles dormant or trigger new hair growth,” said Maksim Plikus, Ph.D., UCI professor of developmental & cell biology and the study’s corresponding author. “We revealed that the SCUBE3 signaling molecule, which dermal papilla cells produce naturally, is the messenger used to ‘tell’ the neighboring hair stem cells to start dividing, which heralds the onset of new hair growth.”
Jul 2, 2022
A Week At The Most Secretive Conference On Aging
Posted by Kelvin Dafiaghor in categories: biotech/medical, genetics, life extension
One of the events hosted by the GRC this year was the conference called ‘Systemic Processes, Omics Approaches, and Biomarkers in Aging.” It was the inaugural Systems Aging Gordon Research Conference. Held in Newry, Maine, this event is not easy to get to. Many of the scientists on the East Coast of the US needed to spend half a day or more just to get there. There is a reason for this. Often, conferences that are organized in large metropolitan areas with easy access do not have the same level of “pressure cooking” and interactive networking just because many senior scientists tend to be distracted and often leave prematurely. But when they are put together in a remote location, it is not easy to leave and they have no choice but to interact with each other, share knowledge, and come up with new ideas and collaborations.
The level and impact of scientific conferences is often evaluated by the number and quality of the sponsors. And the GRC conference on Aging sported a number of high-profile sponsors including GRC itself, Carl Storm International Diversity Fellowship Program, National Institute on Aging, IOMICS Intelligent Analytics, Zymo Research, Kinexum, Insilico Medicine, Illumina, Aging journal, Impetus Grants, Infinita Life Science and VitaDAO.
With Vadim Gladyshev serving as chairman and Steve Horvath as vice-chairman, the conference set the stage for the field, paving the way for the development of interventions to delay and reverse aging. Vadim is a professor of medicine at Harvard Medical School and director of Redox Medicine at Brigham and Women’s Hospital, while Steve is a professor of human genetics and biostatistics at the University of California — Los Angeles, and a senior scientist at Altos Labs. Both are world-renowned researchers, and spoke and led the discussions at the conference.
Jul 1, 2022
The first CRISPR gene-editing drug is coming—possibly as soon as next year
Posted by Kelvin Dafiaghor in categories: biotech/medical, genetics
The first CRISPR gene-editing drug, designed to treat blood disorders, could be on the market by 2023. Here’s what it means for the future of drug development.
The central dogma of molecular biology explains the flow of genetic information, from DNA to RNA, to make a functional product, a protein.
This Video Explains Central Dogma.
Jul 1, 2022
‘It really feels like a miracle.’ After a decade, CRISPR gene editing races toward a cure
Posted by Dan Breeden in categories: bioengineering, biotech/medical, genetics
The DNA-altering technology has revolutionized life sciences research and is making strides in potential one-and-done treatments for sickle cell disease, genetic liver conditions, and more.
